C4 Therapeutics Announces Chief Financial Officer Succession
05 Setembro 2023 - 5:01PM
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage
biopharmaceutical company dedicated to advancing targeted protein
degradation science to develop a new generation of small-molecule
medicines and transform how disease is treated, today announced the
appointment of Kendra Adams as chief financial officer (CFO),
effective September 18, 2023. She will succeed Lauren White, who
will be leaving C4T to pursue a new role with a commercial-stage
pharmaceutical company.
Ms. Adams joined C4T in November 2020 as senior vice president,
investor relations & corporate communications and a member of
the company’s management team. She has more than twenty-five years
of experience in financial, operational and strategic planning. For
nearly twenty years, Ms. Adams has worked in the biotechnology
sector where she has developed investor relations programs focused
on ensuring investors and external audiences understand the
company’s financial position and capital allocation strategy to
advance research and clinical pipelines. She joined C4T from Agios
Pharmaceuticals, where she held investor relations roles of
increasing responsibility during her tenure. She previously led
investor relations at ARIAD Pharmaceuticals and began her investor
relations career at Amgen. Ms. Adams began her professional career
at General Electric, where she participated in the company’s
intensive Financial Management Program. After GE, she joined KPMG
LLP where she led consulting teams on a variety of financial and
strategic matters. She holds a B.A. in economics from Hamilton
College.
"We look forward to Kendra’s expanded role as our next chief
financial officer and we are excited to further leverage her
strategic decision making and extensive capital markets experience
as we continue to advance our pipeline of degrader medicines,” said
Andrew Hirsch, president and chief executive officer. “I would like
to thank Lauren for building a strong finance and accounting team
and positioning C4T for future success. As we prepare for two
clinical updates later this year, we believe we are well positioned
to further advance our mission and bring transformative medicines
to patients.”
About C4 TherapeuticsC4 Therapeutics (C4T)
(Nasdaq: CCCC) is a clinical-stage biopharmaceutical company
dedicated to delivering on the promise of targeted protein
degradation science to create a new generation of medicines that
transforms patients’ lives. C4T is leveraging its
TORPEDO® platform to efficiently design and optimize
small-molecule medicines that harness the body’s natural protein
recycling system to rapidly degrade disease-causing proteins,
offering the potential to overcome drug resistance, drug
undruggable targets and improve patient outcomes. C4T is advancing
multiple targeted oncology programs to the clinic and expanding its
research platform to deliver the next wave of medicines for
difficult-to-treat diseases. For more information, please
visit www.c4therapeutics.com.
Forward-Looking Statements
This press release contains “forward-looking statements” of C4
Therapeutics, Inc. within the meaning of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements may
include, but may not be limited to, express or implied statements
regarding our ability to develop potential therapies for patients;
the design and potential efficacy of our therapeutic approaches;
the predictive capability of our TORPEDO® platform in the
development of novel, selective, orally bioavailable BiDAC™ and
MonoDAC™ degraders; the potential timing, design and advancement of
our preclinical studies and clinical trials, including the
potential timing for and receipt of regulatory authorization
related to clinical trials and other clinical development
activities including clinical trial commencement; our ability and
the potential to successfully manufacture and supply our product
candidates for clinical trials; our ability to replicate results
achieved in our preclinical studies or clinical trials in any
future studies or trials; regulatory developments in the United
States and foreign countries; the potential timing for updates on
our clinical and research programs; and our ability to fund our
future operations. Any forward-looking statements in this press
release are based on management’s current expectations and beliefs
of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially
and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to: uncertainties related to the initiation,
timing, advancement and conduct of preclinical and clinical studies
and other development requirements for our product candidates; the
risk that any one or more of our product candidates will cost more
to develop or may not be successfully developed and commercialized;
the risk that the results of preclinical studies and/or clinical
trials will or will not be predictive of results in connection with
future studies or trials. For a discussion of these and other risks
and uncertainties, and other important factors, any of which could
cause our actual results to differ from those contained in the
forward-looking statements, see the section entitled “Risk Factors”
in C4 Therapeutics’ most recent Annual Report on Form 10-K and/or
Quarterly Report on Form 10-Q, as filed with the Securities and
Exchange Commission. All information in this press release is as of
the date of the release and C4 Therapeutics undertakes no duty to
update this information unless required by law.
Contacts:Investors: Courtney SolbergSenior
Manager, Investor RelationsCSolberg@c4therapeutics.com
Media: Loraine Spreen Senior Director, Corporate
Communications & Patient
Advocacy LSpreen@c4therapeutics.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/3902e1ed-202b-4b1e-bf38-508d5533ae84
C4 Therapeutics (NASDAQ:CCCC)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
C4 Therapeutics (NASDAQ:CCCC)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024